Alnylam plans clinical trials for RNAi therapeutic
ALN-AT3, Alnylam Pharmaceuticals' RNAi therapeutic in development for the treatment of hemophilia, has shown positive results in a preclinical study in nonhuman primates by increasing thrombin generation as much as fourfold.
Alnylam, Tekmira shake hands at last in $75M deal
Alnylam Pharmaceuticals and Tekmira Pharmaceuticals have shaken hands and settled litigation in a $75 million deal. The two companies have signed a restructured agreement that resolves all litigation and clarifies the intellectual property and licensing issues around Tekmira's lipid nanoparticle technology by terminating all previous agreements and creating a new license agreement.
Alnylam to pay $75M to settle legal squabble over Tekmira's RNAi delivery tech
The legal squabble between Tekmira Pharmaceuticals and Alnylam ($ALNY) over rights to the RNAi delivery technology Alnylam uses has been called off. Alnylam is handing over $65 million in cash along with a potential $10 million near-term payout to resolve the showdown over the IP related to lipid nanoparticle technology.
Are you getting the most out of Phase I?
Thursday Nov. 8 at 11 a.m. EST John Carroll will be discussing this in a webinar with three hands-on trial investigators: Jared Gollob, the vice president of clinical research at Alnylam; Hubert Chen, the VP of clinical development at Aileron (Chen also had worked at Regulus earlier); and Karen Cornelissen, the scientific director at Covance Clinical Research Unit in Leeds, U.K. Click here to register for the webinar.
Genzyme pays $22.5M upfront to bag Asian rights to Alnylam's hot ATTR program
Alnylam revealed that the rare-disease specialists at Genzyme--the biologics arm of pharma giant Sanofi--had stepped in to license Asian rights to its program for ATTR, putting down $22.5 million as an upfront along with an unspecified lineup of milestones.
Alnylam, Tel Aviv U develop RNAi drugs to fight rare blood cancer
Tel Aviv University in Israel says it has worked with Alnylam Pharmaceuticals ($ALNY) and DNA Technologies to concoct a new class of RNAi drugs with a shot at combating mantle cell lymphoma, an incurable blood cancer.
Alnylam reaps $29M harvest in new ag bio deal with Monsanto
Alnylam Pharmaceuticals isn't just about new therapeutics anymore. The Cambridge, MA-based biotech today announced that it had signed on with Monsanto as a strategic partner in the ag bioscience business, putting its gene silencing RNAi technology to work for the multinational operation.
Regulus Therapeutics files for $58M IPO
Regulus Therapeutics capped a busy week of deal-making with a proposed initial public offering of $57.5 million, which the biotech would use in part to fund work on its pipeline of microRNA drugs now in pre-clinical development for cancer, hepatitis C, cardiovascular and fibrotic diseases.
Alnylam Pharmaceuticals hit a development milestone for its VaxiRNA technology, receiving a $3.2 million payment from GlaxoSmithKline.
Tekmira's tech carries Alnylam's RNAi winner
Alnylam Pharmaceuticals ($ALNY) has announced positive clinical results from its U.K. Phase I trial of an infusion of ALN-TTR02, an RNAi therapeutic in development for the treatment of TTR-mediated amyloidosis (ATTR). The therapeutic was delivered using Tekmira Pharmaceuticals' ($TKMR) LNP technology.